Boysen Bio ApS: Financial statements 2021
CVR: 38655590
Source: annual report 2021, Danish Business Authority
01/07/2020 – 30/06/2021
Boysen Bio ApS (CVR 38655590) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -4,382 and a net result of DKK -4,039 compared with DKK -3,598 the year before. Equity in the 2021 report amounted to DKK 21,339. The solvency ratio was 2.7%.
- Gross Profit
- DKK -4,382
- Profit/Loss
- DKK -4,039
- Equity
- DKK 21,339
- Total Assets
- DKK 782,290
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -4 t. | -4 t. | 21 t. | - |
| 2020 | - | -4 t. | -4 t. | 25 t. | - |
| 2019 | - | -9 t. | -18 t. | 29 t. | - |
Official annual report
Find more companies like Boysen Bio ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
On October 1, 2021, the company changed its name from Boysen Bio IVS to Boysen Bio ApS.
About Boysen Bio ApS
Boysen Bio ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2017. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named Boysen Bio IVS and GlyProVac IVS. The management consists of Anders Boysen. The company is owned by Anders Boysen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -4,142 and a net result of DKK -4,142 compared with DKK -4,968 the year before. Equity in the 2025 report amounted to DKK 42,055.